Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2012-03-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals
NCT04960527
Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function
NCT02381860
Pharmacokinetics and Pharmacodynamics of Anthocyanins
NCT03650140
To Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Vascular Function.
NCT02234648
Influence of Tart Cherry Juice Intervention on Vascular Function
NCT04840160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be required to attend the laboratory at a range of time points over two periods of 96 hours, separated by a 7 day washout period, to provide blood samples. In order to provide a baseline sample, participants will attend the laboratory in the morning following an overnight fast and voiding of any urine. Following this participants will be given 30mls (30 mls provides 323 mg/380 µmol of anthocyanins) of tart cherry juice or placebo, diluted with 60 mls of water to consume within 10 minutes. Participants will be required to consume identical dosages of the supplement immediately prior to evening meals and breakfasts (or same time each morning following blood sampling if non-breakfast eater) over the next 96 hours. Further blood and urine samples will be collected at 1, 2, 3, 5, 8, 24, 26, 48, 50, 72, 74 and 96 hours and will require participants to return to the laboratory at each of these time points. Following the first period of supplementation participants will complete a 7 day washout period in which they will not be required to attend the laboratory. Following the washout period they will repeat the supplementation period consuming the supplement they did not receive during the first period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low dose
Montmorency cherry concentrate, 30 mls
Montmorency cherry concentrate
Tart Montmorency cherry juice concentrate
higher dose
Montmorency cherry concentrate, 60 mls
Montmorency cherry concentrate
Tart Montmorency cherry juice concentrate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montmorency cherry concentrate
Tart Montmorency cherry juice concentrate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northumbria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Glyn Howatson
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glyn Howatson, PhD
Role: PRINCIPAL_INVESTIGATOR
Northumbria University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northumbria University
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
914
Identifier Type: OTHER
Identifier Source: secondary_id
RE10-01-12554
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.